Permira to fund TBS buyout via levloan market in rude health

Pantheon Healthcare, the pharmaceutical developer owned by Permira, is marketing a €300m loan to finance the acquisition of Telematic and Biomedical Services with bankers saying demand for leveraged loans shows no signs of abating.

  • By Victor Jimenez
  • 17 Jul 2017

Since Permira got its hands on Pantheon in 2014, it has played an active role in the consolidation of the private healthcare services industry in Italy. TBS Group, which provides integrated support in clinical engineering, will become Pantheon’s second acquisition in the sector.

On May 12, Permira ...

Please take a trial or subscribe to access this content.

Contact our subscriptions team to discuss your access: subs@globalcapital.com

Corporate access

To discuss GlobalCapital access for your entire department or company please contact our subscriptions sales team at: subs@globalcapital.com or find out more online here.

Bookrunners of European Leveraged Loans

Rank Lead Manager Amount $m No of issues Share %
  • Last updated
  • 24 Jul 2017
1 BNP Paribas 11,353.22 62 6.48%
2 Goldman Sachs 10,847.70 40 6.19%
3 JPMorgan 9,883.17 41 5.64%
4 Deutsche Bank 8,939.52 52 5.10%
5 Credit Agricole CIB 8,436.06 46 4.81%

Bookrunners of European HY Bonds

Rank Lead Manager Amount €m No of issues Share %
  • Last updated
  • 25 Jul 2017
1 JPMorgan 5,262.65 41 8.52%
2 Goldman Sachs 4,273.93 33 6.92%
3 Deutsche Bank 4,249.17 39 6.88%
4 Credit Suisse 3,915.70 42 6.34%
5 Barclays 3,740.83 31 6.05%

Bookrunners of Dollar Denominated HY Bonds

Rank Lead Manager Amount $m No of issues Share %
  • Last updated
  • 25 Jul 2017
1 JPMorgan 22,011.32 165 11.16%
2 Citi 17,958.06 133 9.10%
3 Bank of America Merrill Lynch 15,724.51 136 7.97%
4 Barclays 13,657.72 88 6.92%
5 Goldman Sachs 13,596.26 99 6.89%